Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will be holding an Investor Symposium for investors and analysts today at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
The Investor Symposium, titled “The clinical significance of SFX-01” will begin at 9.15am. If you wish to attend the event, please contact Buchanan on 0207 466 500 or email tillya@buchanan.uk.com